Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Xilio Therapeutics, Inc. (XLO)
Company Research
Source: Yahoo! Finance
developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective December 1, 2024, the company granted non-qualified stock options to purchase 8,400 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $1.09 per share, which is equal to the closing price of the company's common stock on November 29, 2024. Each stock option will have a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying each stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date. The stock options are subject to the terms and conditions of Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, as well as t
Show less
Read more
Impact Snapshot
Event Time:
XLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XLO alerts
High impacting Xilio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
XLO
News
- Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI [Yahoo! Finance]Yahoo! Finance
- Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI GlobeNewswire
- Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer [Yahoo! Finance]Yahoo! Finance
- Xilio Therapeutics Appoints Caroline Hensley as Chief Legal OfficerGlobeNewswire
- After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright [Yahoo! Finance]Yahoo! Finance
XLO
Sec Filings
- 12/19/24 - Form 4
- 12/19/24 - Form SCHEDULE
- 12/19/24 - Form 8-K
- XLO's page on the SEC website